ISOTRETINOIN AND AESTHETIC PROCEDURES: TIME TO RETHINK THE RULES?

Acne is one of the most prevalent dermatological conditions worldwide. It affects an estimated 85% of people between the ages of 12 and 24, and its psychological burden can rival that of chronic systemic disease. Post-acne scarring, in turn, becomes a therapeutic challenge in its own right, significantly affecting patients' quality of life. Isotretinoin, a vitamin A derivative, remains the most effective systemic option for severe and treatment-resistant acne, and clinical interest in its use continues to grow.

For nearly four decades, dermatologists and skincare practitioners operated under a firm consensus: no invasive procedures during or after a course of isotretinoin. The recommended waiting period was 6 to 12 months. This practice originated in the 1980s and early 1990s, when case reports began appearing in the literature describing atypical keloid formation, impaired wound healing, and unusual facial scarring following dermabrasion, argon laser treatment, and chemical peels performed while patients were taking the drug [2, 3].

These observations became embedded in clinical guidelines — including consensus recommendations from professional organizations [5] — even though the underlying evidence remained largely anecdotal.

Study aim and design

A systematic review published in the Journal of Cosmetic Dermatology in 2025 [1] set out to address three key questions:

whether the recommendation to delay cosmetic procedures for 6–12 months after isotretinoin therapy is actually supported by evidence;
what dermatological adverse events occur when systemic isotretinoin treatment is combined with skin procedures;
what isotretinoin doses and timing intervals can be considered appropriate for different types of intervention.

The authors searched PubMed, Scopus, Web of Science, and Embase, including original studies published through June 2023. After screening, 34 studies with a combined total of 1,563 patients who had undergone skin procedures while on isotretinoin were included. The study designs ranged from clinical trials and prospective and retrospective cohort studies to case series. Evidence quality was assessed using the Oxford Levels of Evidence.

Key findings

The review's central conclusion was unexpectedly reassuring. For a broad range of procedures — laser hair removal, ablative and nonablative fractional lasers, superficial and medium-depth chemical peels, manual dermabrasion, dermatologic surgery, fractional microneedling radiofrequency, microdermabrasion, and dermarolling — the authors found no adequate evidence to support a six-month waiting period. Across most studies, adverse events were transient: erythema, edema, crusting, peeling, dry skin and lips, and cheilitis. Post-inflammatory hyperpigmentation was also reported but resolved spontaneously in most cases.

Keloid formation deserves particular attention, as it was the primary driver of decades of caution. Across the entire cohort of 1,563 patients, only three cases of keloid formation were documented: one following a glycolic acid peel, one after an ablative radiofrequency procedure, and one after treatment with a pulsed dye laser (PDL, 585 nm) combined with Nd: YAG (1064 nm). In the last case, the authors noted that the keloid was most likely attributable to the acne itself rather than the procedure [4]. This event rate does not support a systemic risk of keloid formation linked to the combination of isotretinoin and cosmetic procedures.

Equally noteworthy, several studies have found that concurrent use of isotretinoin and procedural treatment produced greater skin improvement and higher patient satisfaction than either approach alone.

What remains restricted

The authors are clear that these findings do not amount to a blanket removal of restrictions. Full-field ablative lasers, mechanical dermabrasion, and ablative radiofrequency procedures are still not recommended during isotretinoin therapy — the evidence base is insufficient and the risk of adverse events may be higher. Appropriate waiting periods for these modalities remain to be defined in future research.

The authors also recommend using lower isotretinoin doses when procedures are planned — generally no more than 0.5 mg/kg/day — since higher doses were historically associated with a greater incidence of adverse events. Particular caution is warranted for any invasive procedure in patients with a personal or family history of keloid formation, regardless of the procedure type.

Limitations of the review

The authors acknowledge that the overall level of evidence was low. A substantial share of the included studies were case series and nonrandomized trials with small sample sizes. Variability in isotretinoin doses, laser parameters, peel depths, and outcome assessment methods made direct comparisons difficult. No consensus exists on precise safe intervals for specific procedure types. The findings should be read as grounds for revisiting overly conservative restrictions — not as a definitive green light.

A further limitation was the inconsistent characterization of patients' skin condition. The included studies varied considerably in their clinical indications: procedures were performed both to treat active acne and to address post-acne scarring. Because the authors did not apply a standardized classification of disease activity or severity, the review does not allow conclusions about the safety of performing procedures directly on actively inflamed lesions. Its findings should not be automatically extended to patients with active inflammatory acne.

Implications for clinical practice

This systematic review has direct clinical relevance. A six-month "quarantine" often delays the treatment of post-acne scarring at precisely the time when patients are most motivated and receptive to comprehensive care. For practitioners working with patients on isotretinoin, the key message is this: the choice of procedure, its parameters, the isotretinoin dose, and the patient's individual history should all be weighed together — and it is these factors, not a blanket time-based restriction, that should drive clinical decision-making.

That said, the absence of a need for prolonged waiting with certain procedures does not mean those procedures should be performed over actively inflamed lesions. Acne activity and overall skin condition must be assessed before any intervention; the conclusions of this review are not a substitute for individualized clinical judgment about whether a specific procedure is appropriate for a specific patient.

When the method and dose are chosen thoughtfully, there is no compelling reason to postpone most modern cosmetic procedures for six months or more.

Conclusion

Fear of keloid formation and impaired wound healing — rooted in isolated case reports from the 1980s — held back combined approaches to treating acne and its sequelae for decades. The 2025 systematic review makes a case for rethinking that paradigm: for most current cosmetic procedures, there is no convincing evidence that a six-month wait is necessary, and the risk of serious complications, including keloid formation, appears to be very low when appropriate parameters are used. The call for caution remains — particularly for aggressive ablative procedures and patients with individual risk factors. The field is still open for larger, higher-quality studies.